TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06052878

Intervention type: OTHER
Intervention: Parental telephone interview with standardized parental questionnaire from the Behaviour Rating Inventory of Executive Function (BRIEF)
Description: The Behaviour Rating Inventory of Executive Function (BRIEF) is a parental questionnaire that assesses the executive functions of children aged 5 to 18 years old. It consists of 86 questions grouped into 8 scales: inhibition, flexibility, emotional control, initiation, material organization, working memory, planning/organization, and monitoring. It provides information on a global scale (score) regarding subtle and subclinical changes in various executive functions.

Intervention type: OTHER
Intervention: Parental telephone interview with standardized parental questionnaire from the Behaviour Rating Inventory of Executive Function (BRIEF)
Description: The Behaviour Rating Inventory of Executive Function (BRIEF) is a parental questionnaire that assesses the executive functions of children aged 5 to 18 years old. It consists of 86 questions grouped into 8 scales: inhibition, flexibility, emotional control, initiation, material organization, working memory, planning/organization, and monitoring. It provides information on a global scale (score) regarding subtle and subclinical changes in various executive functions.

Intervention type: OTHER
Intervention: Parental telephone interview with standardized parental questionnaire from the Behaviour Rating Inventory of Executive Function (BRIEF)
Description: The Behaviour Rating Inventory of Executive Function (BRIEF) is a parental questionnaire that assesses the executive functions of children aged 5 to 18 years old. It consists of 86 questions grouped into 8 scales: inhibition, flexibility, emotional control, initiation, material organization, working memory, planning/organization, and monitoring. It provides information on a global scale (score) regarding subtle and subclinical changes in various executive functions.

Intervention type: OTHER
Intervention: Parental questionnaire about their child's cognitive functioning in their daily life and medical history.
Description: Standardized questionnaire includes : The child's medical history and cognitive functioning (at school, parental home, and during extracurricular activities), home environment, parent's child socioeconomic status and emotional climate.

Intervention type: OTHER
Intervention: Parental questionnaire about their child's cognitive functioning in their daily life and medical history.
Description: Standardized questionnaire includes : The child's medical history and cognitive functioning (at school, parental home, and during extracurricular activities), home environment, parent's child socioeconomic status and emotional climate.

Intervention type: OTHER
Intervention: Parental questionnaire about their child's cognitive functioning in their daily life and medical history.
Description: Standardized questionnaire includes : The child's medical history and cognitive functioning (at school, parental home, and during extracurricular activities), home environment, parent's child socioeconomic status and emotional climate.
Study: NCT02059694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronidase

Intervention type: OTHER
Group type: OTHER
Intervention: 2 mL of lidocaine 2% with epinephrine 1:100,000 without rHuPH20
Study: NCT06526715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Morton extension
Description: A Morton extension with a height of 5 mm was insert from the proximal area of the first metatarsal head to the base of the proximal phalanx of the Hallux of the subjects' bare feet using a paper bandage. The material, shape, size, and thickness of the Morton Extension were the same.
Study: NCT06529640

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCTG followed by coronally postionting flap
Description: The SCTG will be harvested from the palate followed by coronally postionting flap
Study: NCT05935098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A3055
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A3055
Description: Administered intravenously
Study: NCT06529640

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: periosteal flap followed by coronally postionting flap
Description: he periosteal pedicle graft obtained is then turned over the exposed root surface then followed by coronally postionting flap
Study: NCT05935098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously
Study: NCT05051566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.
Study: NCT04902339

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Oriented Recovery Enhancement
Description: 8 weeks of therapy integrating mindfulness, reappraisal, and savoring skills.
Study: NCT05051566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Administered orally.
Study: NCT04902339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement
Description: 8 weeks of therapy integrating mindfulness, reappraisal, and savoring skills.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Near-infrared spectroscopy neurofeedback during savoring practice.
Study: NCT06082050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YOLT-201
Description: Infusion of YOLT-201 at Day 1。
Study: NCT06043050

Intervention type: DRUG
Intervention: Platelets
Description: Observational data: all platelet transfusions recorded in routine care medical file data.
Study: NCT04902339

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy
Description: 8 weeks of supportive, process-oriented psychotherapy.
Study: NCT05956340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Research interview
Description: Research interview to capture speech data with high quality cardioid headset microphone
Study: NCT06438861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vibegron 75mg
Description: Each patient will undergo intradetrusor onabotulinumtoxinA injections of 100U either in the office or in the operating room depending on patient and provider preference. Patients will begin taking vibegron 75mg daily or a placebo pill daily starting the day of their procedure and continue for 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each patient will undergo intradetrusor onabotulinumtoxinA injections of 100U either in the office or in the operating room depending on patient and provider preference. Patients will begin taking vibegron 75mg daily or a placebo pill daily starting the day of their procedure and continue for 3 months.
Study: NCT05017740

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICSI
Description: In ICSI, the sperm is chosen based on motility and gross morphology to be inseminated directly into the cytoplasm of the oocyte.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PICSI
Description: In PICSI, the sperm is selected via hyaluronic binding before insemination into the cytoplasm of the oocyte.
Study: NCT06529835

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuroSpan Bridge
Description: The implant is used to connect peripheral nerve discontinuities. It is designed to be an interface between the nerve and surrounding tissue and to create a conduit for axonal growth across a nerve gap.~The NeuroSpan Bridge is a novel scaffold to support regeneration that mimics the natural bio- architecture, providing multiple channels that are strictly linear so that axonal position is accurately maintained across the full length of the scaffold - over any length - to re-enter the distal nerve stump.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuroSpan Bridge
Description: The implant is used to connect peripheral nerve discontinuities. It is designed to be an interface between the nerve and surrounding tissue and to create a conduit for axonal growth across a nerve gap.~The NeuroSpan Bridge is a novel scaffold to support regeneration that mimics the natural bio- architecture, providing multiple channels that are strictly linear so that axonal position is accurately maintained across the full length of the scaffold - over any length - to re-enter the distal nerve stump.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuroGen Nerve Guide
Description: The NeuraGen Nerve Guide is a resorbable implant for the repair of 0.5-1.0cm peripheral nerve discontinuities. NeuraGen Nerve Guide provides a protective environment for peripheral nerve repair after injury. It is designed to be an interface between the nerve and surrounding tissue and to create a conduit for axonal growth across a nerve gap. The semi-permeable type 1 collagen membrane allows for controlled resorption, appropriate nutrient diffusion and retention of representative Nerve Growth Factor.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Autograft
Description: A nerve autograft is a surgical procedure that involves transplanting a segment of a patient's own sensory nerve tissue to repair a damaged peripheral nerve injury measuring 1.1-3.0cm. It is designed to be an interface between the nerve and surrounding tissue and to create a conduit for axonal growth across a nerve gap
Study: NCT06524024

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor polypeptide pool induced DC-CTL cell injection
Description: In this study, DC-CTL cells were injected once a day for two consecutive days, 1-2 days after study participants received a conventional antitumor regimen, and subcutaneous injections of DC cells were administered before a second infusion of DC-CTL cells. A total of about 4-6 cycles of cell infusion are required
Study: NCT04854980

Intervention type: OTHER
Intervention: Blood Sample
Description: Blood sample, 2- to 5 tea spoon full (between 10 to 25 mL approximately) between 43 to 96 days after first dose of the vaccine.
Study: NCT05562440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focus Group Discussion
Description: Each focus group will consist up to five participants in every session, two sessions each for both low and high risk group. Every FGD sessions will last for 1 to 2 hours and be conducted in Indonesian, and will be recorded. Both groups will be asked the following questions: 1) What is your opinion regarding the clarity of information in the dummy breast cancer risk prediction report?; 2) What is your opinion regarding the completeness of information in the dummy breast cancer risk prediction report?; and 3) What is your impression regarding the results presented in the dummy breast cancer risk prediction report?.
Study: NCT05806333

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FAPI PET
Description: Drug: 18F-FAPI 18F-FAPI were injected into the patients before the PET/CT scans
Study: NCT06035133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CapeOX + cetuximab
Description: CapeOX + cetuximab for RAS wild-type patients and CapeOX + cetuximab for MSI-H patients. The CapeOX regimen: Oxaliplatin 130 mg/m2, intravenous injection, day 1; capecitabine 1000 mg/m2, oral, twice daily, days 1 through 14; once every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CapeOX + bevacizumab
Description: CapeOX + bevacizumab for RAS mutant patients. The CapeOX regimen: Oxaliplatin 130 mg/m2, intravenous injection, day 1; capecitabine 1000 mg/m2, oral, twice daily, days 1 through 14; once every 3 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiotherapy
Study: NCT05958784

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Phenylalanine
Description: 100 mg/kg
Study: NCT05738564

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine Inhalation Solution
Description: epinephrine prepared solution mixed with lidocaine (EL) Otrivin adult nasal drops 0.1Otrivin adult nasal drops 0.1%, 10 ml of 1 mg/ml; Novartis Consumer Health, UK Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK) in each nostril in the pre-induction room just before the induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine Inhalation Solution
Description: epinephrine prepared solution mixed with lidocaine (EL) Otrivin adult nasal drops 0.1Otrivin adult nasal drops 0.1%, 10 ml of 1 mg/ml; Novartis Consumer Health, UK Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK) in each nostril in the pre-induction room just before the induction of anesthesia
Study: NCT06186440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin Plus Temozolomide
Description: Cisplatin Plus Temozolomide . Cisplatin 20mg/mCisplatin days 1-5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Temozolomide
Study: NCT04799470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel DBS stimulation patterns
Description: Stimulation patterns
Study: NCT05161260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Breathing
Description: For the12 weeks, participants will be asked to use the mobile study app, completing 3, 10 minute exercises, 5 days a week. Participants in the Yoga Breathing group will practice a breathing exercise guided by the mobile study application. The application will also send nudges and reminders throughout the day. Participants will engage with the research study app along with other participants in groups of 2-7 at their own convenience. Participants may practice their breathing activity with either a group of participants, through the video conferencing feature of the app, or on their own. The study instructor may join sessions on a random basis to ensure compliance with the technique and to clarify any questions participants may have.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Control
Description: For the12 weeks, participants will be asked to use the mobile study app, completing 3, 10 minute exercises, 5 days a week. Participants in the Attention Control group will practice a mindfulness exercise guided by the mobile study application. The application will also send nudges and reminders throughout the day. Participants will engage with the research study app along with other participants in groups of 2-7 at their own convenience. Participants may practice their mindfulness activity with either a group of participants, through the video conferencing feature of the app, or on their own. The study instructor may join sessions on a random basis to ensure compliance with the technique and to clarify any questions participants may have.
Study: NCT06152159

Intervention type: OTHER
Intervention: data collection
Description: Data collection
Study: NCT04921683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BX Pulsar 1002 (LIFUP) Low intensity Focused Ultrasound Pulsation
Description: Administration of LIFUP will be performed at the bedside using frameless stereotaxy. Specifically, the LIFUP transducer will be fit to the patient's head employing adjustable straps, and will be positioned over the patient's left temporal bone, over the temporal window in order to minimize bone absorption and refraction. Accurate aiming will be ensured employing the BrainSight neuronavigation device, customized for tracking our LIFUP transducer (total \~10 min). Once satisfactory aiming is achieved, the LIFUP exposure will be initiated employing the settings described previously (which meet the FDA safety limits: ISPPA \<= 190W/cm2, ISPTA \<= 0.72W/cm2). Accurate aiming will be monitored in real-time throughout exposure using the Brain Sight Neuronavigation interface.
Study: NCT06278402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Oral tofacitinib 5mg twice daily for treatment of alopecia areata, totalis and universalis.
Study: NCT06208761

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triphala capsule supplementation and high-intensity interval training
Description: Triphala capsule supplementation is categorized in dietary supplement but and high-intensity interval training is included as other

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Triphala capsule supplementation and high-intensity interval training
Description: Triphala capsule supplementation is categorized in dietary supplement but and high-intensity interval training is included as other

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triphala capsule supplementation and high-intensity interval training
Description: Triphala capsule supplementation is categorized in dietary supplement but and high-intensity interval training is included as other

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triphala capsule supplementation and high-intensity interval training
Description: Triphala capsule supplementation is categorized in dietary supplement but and high-intensity interval training is included as other
Study: NCT06177041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M108 monoclonal antibody
Description: M108 monoclonal antibody will be administered as a minimum 2-hour IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a minimum 2-hour IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered as a 2-hour IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered as a 2-hour IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered orally twice daily (bid).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine will be administered orally twice daily (bid).
Study: NCT06360731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4-7-8 breathing exercise technique and informative session on tinnitus
Description: Participants in experimental group will be individually provided with informative session on tinnitus for one hour by researchers. During the informative session, the participants will be given general information about tinnitus and will be informed about the possible causes, symptoms, diagnosis, therapy, or treatment processes, and coping methods. The participants will be also given a printed informative brochure on tinnitus. In the same session, after one hour of informative session, the 4-7-8 breathing exercise method will be demonstrated by the same researchers. In addition, a video showing how to perform the 4-7-8 breathing exercise technique will be sent as a text message to their cell phones.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informative session on tinnitus
Description: Participants in control group will be individually provided with informative session on tinnitus only for one hour by researchers G.K. and G.S.U. from both clinics. During the informative session, the participants will be given general information about tinnitus and inform about the possible causes, symptoms, diagnosis, therapy, or treatment processes, and coping methods. The participants will be also given a printed informative brochure on tinnitus.
Study: NCT06371547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching Exercise
Description: Participants will perform different types and durations of gastrocnemius muscle stretching exercises according to their assigned groups for two weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching Exercise
Description: Participants will perform different types and durations of gastrocnemius muscle stretching exercises according to their assigned groups for two weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching Exercise
Description: Participants will perform different types and durations of gastrocnemius muscle stretching exercises according to their assigned groups for two weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching Exercise
Description: Participants will perform different types and durations of gastrocnemius muscle stretching exercises according to their assigned groups for two weeks.
Study: NCT04780659

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comirnaty (COVID-19, mRNA vaccine)
Description: Comirnaty will be administered two times, one at Day 0 and the second dose at Day 21.
Study: NCT06298279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tunneled Delivery
Description: Participants will be offered a pre-determined pathway to completing the 8-week course

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tunneled Delivery
Description: Participants will be offered a pre-determined pathway to completing the 8-week course

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Delivery
Description: Participants will be able to complete course modules at their own pace and in the order that most interests them.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Delivery
Description: Participants will be able to complete course modules at their own pace and in the order that most interests them.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Resources
Description: Participants will receive the resources as typically included in the Self-Guided PSP Wellbeing Course.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Resources
Description: Participants will receive the resources as typically included in the Self-Guided PSP Wellbeing Course.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Social Learning Resources
Description: Participants will receive additional intervention content.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Social Learning Resources
Description: Participants will receive additional intervention content.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Self-Guided ICBT
Description: An ICBT course that is completed without the guidance of a therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Self-Guided ICBT
Description: An ICBT course that is completed without the guidance of a therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Self-Guided ICBT
Description: An ICBT course that is completed without the guidance of a therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Self-Guided ICBT
Description: An ICBT course that is completed without the guidance of a therapist.